Smith & Nephew PLC (SNN)
24.78
+0.34
(+1.39%)
USD |
NYSE |
May 03, 16:00
24.80
+0.02
(+0.06%)
After-Hours: 20:00
Smith & Nephew Debt to Equity Ratio: 0.553 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.553 |
| June 30, 2023 | 0.5439 |
| December 31, 2022 | 0.5088 |
| June 30, 2022 | 0.5034 |
| December 31, 2021 | 0.5643 |
| June 30, 2021 | 0.6335 |
| December 31, 2020 | 0.6583 |
| June 30, 2020 | 0.4921 |
| December 31, 2019 | 0.3651 |
| Date | Value |
|---|---|
| June 30, 2019 | 0.44 |
| December 31, 2018 | 0.3006 |
| June 30, 2018 | 0.3244 |
| December 31, 2017 | 0.3122 |
| June 30, 2017 | 0.397 |
| December 31, 2016 | 0.4151 |
| June 30, 2016 | 0.4511 |
| December 31, 2015 | 0.3732 |
| June 30, 2015 | 0.3947 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.3651
Minimum
Dec 2019
0.6583
Maximum
Dec 2020
0.5262
Average
0.5264
Median
Debt to Equity Ratio Benchmarks
| AstraZeneca PLC | 0.8895 |
| Adaptimmune Therapeutics PLC | 0.00 |
| Biodexa Pharmaceuticals Plc | 0.00 |
| Verona Pharma PLC | -- |
| NuCana PLC | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 9.987B |
| Total Liabilities (Quarterly) | 4.77B |
| Shareholders Equity (Quarterly) | 5.217B |
| Current Ratio | 1.774 |
| Net Debt Paydown Yield | -0.47% |